Evidence map›Paper›PMID 41737540›Full record

ArticleBreast cancer (Dove Medical Press)2026

Clonal Dynamics and Molecular Heterogeneity of Metaplastic Breast Cancer: Focus on TP53 and PIK3CA Truncal Mutations.

Rupei Ye, Xinzhi Dai, Zihan Yang, Dandan Zhang, Zhimin Hu, Yehui Liao, Zhihui Yang

Abstract read
In one paragraph

Article in Breast cancer (Dove Medical Press), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Rupei Ye *Department of Pathology, The Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, 646000, People's Republic of China.ORCID 0000-0002-6133-7737
Xinzhi Dai *Department of Pathology, Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, People's Republic of China.
Zihan YangDepartment of Pathology, The Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, 646000, People's Republic of China.
Dandan ZhangDepartment of Pathology, The Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, 646000, People's Republic of China.
Zhimin HuSchool of Basic Medical Sciences, Southwest Medical University, Luzhou, Sichuan, 646000, People's Republic of China.ORCID 0000-0001-9665-2609
Yehui LiaoDepartment of Orthopedics, The Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, 646000, People's Republic of China.
Zhihui YangDepartment of Pathology, The Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, 646000, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Metaplastic breast carcinoma (MBC) is a rare and aggressive subtype of triple-negative breast cancer with distinct molecular features that remain incompletely characterized, hindering the development of effective therapies. Methods: We integrated clinicopathological data with next-generation sequencing (NGS) of 437 cancer-related genes performed on 25 tumor samples (16 primary, 8 lymph node metastases, 1 distant metastasis) from 17 MBC patients. Functional enrichment analysis was conducted to identify key signaling pathways. Results: Recurrent alterations were identified in Conclusion: This study delineates the distinct mutational landscape and clonal evolution patterns of MBC, underpinned by truncal mutations in

Indexed as

clinicopathological characteristicsfunctional enrichment analysismetaplastic breast carcinomamolecular characteristicsnext-generation sequencingPIK3CATP53

Identifiers

PMID41737540
PMCPMC12927796

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.